Dr Andrew Furness is a Consultant Medical Oncologist specialising in the treatment of cancers of the kidney and skin.

Dr Furness completed his undergraduate medical training at Guy’s, King’s and St Thomas’ School of Medicine, London; where he also undertook an intercalated BSc in Human Physiology.

Following completion of core training in internal medicine, he undertook specialist training in Medical Oncology at The Royal Marsden.

In 2013, he was awarded the Sam Keen Foundation Fellowship and spent four years studying Cancer Immunology at University College London Cancer Institute. During this time he studied the immune landscape of human tumours and made fundamental contributions to current understanding of the mechanisms underlying the activity of immune-modulatory antibody-based therapies; he was awarded a PhD in 2018.

In 2019, he was appointed as a Consultant in Medical Oncology and Solid Tumour Cell Therapy lead. He is Associate Honorary Faculty and Clinical Lead of the Centre for Translational Immunotherapy at the Institute of Cancer Research, faculty member of the ESMO Tumour Immunology/Immunotherapy and Investigational Immunotherapy groups and sits on the ESMO Precision Medicine and Translational research working group.

His research interests are centred in translational immunology and the clinical application of cell-based therapies for solid tumours.